Johnson & Johnson Medical Devices Companies introduced Cerenovus, its new neurovascular business, at the Society of NeuroInterventional Surgery 14th Annual Meeting (SNIS; 24–28 July, Colorado Springs, USA).
Cerenovus, a name derived from the Latin words for ‘new’ and ‘brain’, will focus on delivering innovative therapies for haemorrhagic and ischaemic stroke patients.
“Our neurovascular business is evolving and Cerenovus reflects our bold new vision, positioning and priorities,” said Shlomi Nachman, Company Group Chairman of Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions. “Inspired by how quickly a stroke can affect a person’s mind and our commitment to reducing the devastating impact, Cerenovus aims to help physicians give stroke patients a new lease on life.”
According to a press release, the Johnson & Johnson Medical Devices Companies are committed to neurovascular care, having expanded Cerenovus’s product portfolio in the last year with targeted investments. The recent acquisitions of Pulsar Vascular, with a specialty in the endovascular treatment of wide-neck bifurcation aneurysms, and Neuravi, offering extensive expertise and knowledge in acute ischaemic stroke with its EmboTrap Revascularization Platform, greatly extend Cerenovus’s abilities to address unmet clinical needs in these areas.
Johnson & Johnson’s neurovascular business was previously under the name Codman Neuro.